| abstract |
The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using IgE antagonists, e.g., ligelizumab. Also disclosed herein are IgE antagonists, e.g., IgE antibodies, such as ligelizumab, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods. |